A child with Guillain-Barre syndrome treated with intravenous immune g
lobulin (IVIG) developed neutropenia (absolute neutrophil count = 390)
, which resolved 3 days after completion of the therapy, Potential mec
hanisms for the development of neutropenia during the use of IVIG ther
apy are discussed. In this case, testing of the IVIG used revealed the
presence of a high concentration of anti-neutrophil antibodies compar
ed to other samples, It is recommended that white blood cell and neutr
ophil counts be monitored daily during the use of such therapy.